Roth MKM raised the firm’s price target on Biote to $9 from $8 and keeps a Buy rating on the shares. The company’s Q4 results were “largely as expected” after its January pre-announcement, the analyst tells investors in a research note. The firm remains “positive” on the stock given its compelling valuation and still strong financial profile, especially when accounting for its planned share repurchases, Roth MKM added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BTMD:
- 3 Best Stocks to Buy Now, 2/22/2024, According to Top Analysts
- Biote Corp. Settles Litigation and Repurchases Founder’s Shares
- B. Riley starts Biote with Buy on horome replacement therapy potential
- Biote initiated with a Buy at B. Riley
- Biote initiated with a Buy at Jefferies with ‘platform revving up’
